BACKGROUND: The current study attempted to evaluate the association between IL-10 promoter gene polymorphism and transplant outcomes including the occurrence of chronic graft-versus-host disease (GVHD) and its clinical course during systemic immunosuppressive treatment (IST) among 60 recipients of cytokine-mobilized peripheral blood stem cell (PBSC) from HLA-matched sibling donors. METHODS: We analyzed 3 single-nucleotide polymorphisms in proximal region of IL-10 promoter gene (-1082/-819/-592). RESULTS: In the current study, only two haplotypes (1082*A/819*T/592*A [ATA] and 1082*A/819*C/592*C [ACC]) were found. An increased occurrence of chronic GVHD was noted dependent on the IL-10 haplotypes (43% vs. 68% vs. 96% in ACC/ACC vs. ATA/ACC vs. ATA/ATA haplotype, P=0.003). In a logistic regression based on multinomial model, ATA/ATA homozygote had 7-fold increasing risk of the development of chronic GVHD compared with ACC/ACC homozygote. The incidence of chronic GVHD at 1 year was 46%+/-20%, 64%+/-10%, and 82%+/-5% in ACC/ACC, ATA/ACC and ATA/ATA group, respectively (P=0.0266). Plus, the duration of systemic IST was significantly shorter in recipients without ATA-haplotype comparing with those with ATA haplotype (339 days vs. 1,146 days, P=0.0091). CONCLUSION: IL-10 promoter gene polymorphism was found to be apparently associated with chronic GVHD after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
BACKGROUND: The current study attempted to evaluate the association between IL-10 promoter gene polymorphism and transplant outcomes including the occurrence of chronic graft-versus-host disease (GVHD) and its clinical course during systemic immunosuppressive treatment (IST) among 60 recipients of cytokine-mobilized peripheral blood stem cell (PBSC) from HLA-matched sibling donors. METHODS: We analyzed 3 single-nucleotide polymorphisms in proximal region of IL-10 promoter gene (-1082/-819/-592). RESULTS: In the current study, only two haplotypes (1082*A/819*T/592*A [ATA] and 1082*A/819*C/592*C [ACC]) were found. An increased occurrence of chronic GVHD was noted dependent on the IL-10 haplotypes (43% vs. 68% vs. 96% in ACC/ACC vs. ATA/ACC vs. ATA/ATA haplotype, P=0.003). In a logistic regression based on multinomial model, ATA/ATA homozygote had 7-fold increasing risk of the development of chronic GVHD compared with ACC/ACC homozygote. The incidence of chronic GVHD at 1 year was 46%+/-20%, 64%+/-10%, and 82%+/-5% in ACC/ACC, ATA/ACC and ATA/ATA group, respectively (P=0.0266). Plus, the duration of systemic IST was significantly shorter in recipients without ATA-haplotype comparing with those with ATA haplotype (339 days vs. 1,146 days, P=0.0091). CONCLUSION:IL-10 promoter gene polymorphism was found to be apparently associated with chronic GVHD after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
Authors: Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz Journal: Biol Blood Marrow Transplant Date: 2015-01-30 Impact factor: 5.742
Authors: D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton Journal: Bone Marrow Transplant Date: 2014-03-03 Impact factor: 5.483
Authors: John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin Journal: Immunol Res Date: 2008 Impact factor: 2.829
Authors: Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen Journal: Blood Date: 2016-10-06 Impact factor: 22.113